Literature DB >> 24471776

Simvastatin inhibits transforming growth factor-β1-induced expression of type I collagen, CTGF, and α-SMA in keloid fibroblasts.

Je-Ho Mun1, Young-Mi Kim, Byung-Soo Kim, Jae-Ho Kim, Moon-Bum Kim, Hyun-Chang Ko.   

Abstract

Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor, is used to reduce cholesterol levels. Accumulating evidence has revealed the immunomodulatory and anti-inflammatory effects of simvastatin that prevent cardiovascular diseases. In addition, the beneficial effects of statins on fibrosis of various organs have been reported. However, the functional effect of statins on dermal fibrosis of keloids has not yet been explored. The objective of this study was to determine whether simvastatin could affect dermal fibrosis associated with keloids. We examined the effect of simvastatin on transforming growth factor (TGF)-β1-induced production of type I collagen, connective tissue growth factor (CTGF or CCN2), and α-smooth muscle actin (α-SMA). Keloid fibroblasts were cultured and exposed to different concentrations of simvastatin in the presence of TGF-β1, and the effects of simvastatin on TGF-β1-induced collagen and CTGF production in keloid fibroblasts were determined. The type I collagen, CTGF, and α-SMA expression levels and the Smad2 and Smad3 phosphorylation levels were assessed by Western blotting. The effect of simvastatin on cell viability was evaluated by assessing the colorimetric conversion of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide. Simvastatin suppressed TGF-β1-induced type I collagen, CTGF, and α-SMA production in a concentration-dependent manner. The TGF-β1-induced Smad2 and Smad3 phosphorylation levels were abrogated by simvastatin pretreatment. The inhibition of type I collagen, CTGF, and α-SMA expression by simvastatin was reversed by geranylgeranyl pyrophosphate, suggesting that the simvastatin-induced cellular responses were due to inhibition of small GTPase Rho involvement. A RhoA activation assay showed that preincubation with simvastatin significantly blocked TGF-β1-induced RhoA activation. The Rho-associated coiled kinase inhibitor Y27632 abrogated TGF-β1-induced production of type I collagen, CTGF, and α-SMA. However, Y27632 had no significant effect on TGF-β1-induced phosphorylation of Smad2 and Smad3. In conclusion, the present study suggests that simvastatin is an effective inhibitor of TGF-β1-induced type I collagen, CTGF, and α-SMA production in keloid fibroblasts.
© 2013 by the Wound Healing Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24471776     DOI: 10.1111/wrr.12136

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  19 in total

1.  Simvastatin restored vascular reactivity, endothelial function and reduced string vessel pathology in a mouse model of cerebrovascular disease.

Authors:  Xin-Kang Tong; Edith Hamel
Journal:  J Cereb Blood Flow Metab       Date:  2015-01-07       Impact factor: 6.200

2.  Simvastatin reduces fibrosis and protects against muscle weakness after massive rotator cuff tear.

Authors:  Max E Davis; Michael A Korn; Jonathan P Gumucio; Julie A Harning; Anjali L Saripalli; Asheesh Bedi; Christopher L Mendias
Journal:  J Shoulder Elbow Surg       Date:  2014-09-09       Impact factor: 3.019

3.  Simvastatin and nanofibrous poly(l-lactic acid) scaffolds to promote the odontogenic potential of dental pulp cells in an inflammatory environment.

Authors:  Diana G Soares; Zhanpeng Zhang; Fatma Mohamed; Thomas W Eyster; Carlos A de Souza Costa; Peter X Ma
Journal:  Acta Biomater       Date:  2017-12-30       Impact factor: 8.947

4.  Overexpression of RACK1 inhibits collagen synthesis in keloid fibroblasts via inhibition of transforming growth factor-β1/Smad signaling pathway.

Authors:  Ping Zhou; Lina Shi; Qing Li; Di Lu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

5.  Mycobacterium tuberculosis induces connective tissue growth factor expression through the TLR2-JNK-AP-1 pathway in human lung fibroblasts.

Authors:  Hong-Sheng Lee; Hung-Sheng Hua; Cheng-Hui Wang; Ming-Chih Yu; Bing-Chang Chen; Chien-Huang Lin
Journal:  FASEB J       Date:  2019-08-26       Impact factor: 5.191

Review 6.  MicroRNA-21 in Skin Fibrosis: Potential for Diagnosis and Treatment.

Authors:  Yan Li; Juan Zhang; Yuying Lei; Lechun Lyu; Ruiling Zuo; Ting Chen
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

7.  Methylation of secreted frizzled-related protein 1 (SFRP1) promoter downregulates Wnt/β-catenin activity in keloids.

Authors:  Jiaqi Liu; Huayu Zhu; Hongtao Wang; Jun Li; Fu Han; Yang Liu; Wanfu Zhang; Ting He; Na Li; Zhao Zheng; Dahai Hu
Journal:  J Mol Histol       Date:  2018-02-17       Impact factor: 2.611

Review 8.  Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.

Authors:  Si-Nan Lin; Ren Mao; Chenchen Qian; Dominik Bettenworth; Jie Wang; Jiannan Li; David H Bruining; Vipul Jairath; Brian G Feagan; Min-Hu Chen; Florian Rieder
Journal:  Physiol Rev       Date:  2021-09-27       Impact factor: 37.312

9.  Suppressive effects of induced pluripotent stem cell-conditioned medium on in vitro hypertrophic scarring fibroblast activation.

Authors:  Ye Ren; Chen-Liang Deng; Wei-Dong Wan; Jiang-Hong Zheng; Guang-Yu Mao; Song-Lin Yang
Journal:  Mol Med Rep       Date:  2014-12-18       Impact factor: 2.952

10.  The Combination of Electroacupuncture and Massage Therapy Alleviates Myofibroblast Transdifferentiation and Extracellular Matrix Production in Blunt Trauma-Induced Skeletal Muscle Fibrosis.

Authors:  Na Zhao; Bo Liu; Si-Wen Liu; Wei Zhang; Hua-Nan Li; Geng Pang; Xiong-Fei Luo; Jin-Gui Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-07       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.